MATEON THERAPEUTICS, INC. (MATN) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

(a) On November11, 2016, Mateon Therapeutics, Inc. (the Company)
held a special meeting of the stockholders of the Company (the
Special Meeting) at the offices of the Companys counsel, Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (Mintz Levin), 44
Montgomery Street, 36^th
Floor, San Francisco, California 94104.

(b) Of the 26,544,934 shares of the Companys common stock
entitled to vote at the Special Meeting, 16,515,654 shares were
represented at the meeting in person or by proxy, constituting a
quorum. The voting results for the only matter submitted to vote
at the Special Meeting are as set forth below. This proposal is
described in further detail in the Companys definitive proxy
statement filed with the Securities and Exchange Commission on
October3, 2016.

The stockholders approved a proposal authorizing the adjournment
of the Special Meeting, if a quorum was present, to solicit
additional proxies if there were insufficient votes to approve
the proposal regarding the reverse stock split.

In connection with stockholder approval of the adjournment
proposal described above, the Company elected to adjourn the
Special Meeting until November22, 2016 at 2:00 p.m., local time,
to be held again at the offices of Mintz Levin, 44 Montgomery
Street, 36th Floor, San Francisco, California 94104. The record
date for the Special Meeting remains September15, 2016.

About MATEON THERAPEUTICS, INC. (MATN)